Keith Katkin insider trades
Open-market stock purchases and sales by Keith Katkin, Director at Emergent BioSolutions Inc, from SEC Form 4 filings since Jan 4, 2010.
Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +44%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Apr 30, 2026 | EBS Emergent BioSolutions Inc | Bought (not open market) | — |
| Apr 30, 2026 | EBS Emergent BioSolutions Inc | Sold | $128K |
| Apr 30, 2026 | EBS Emergent BioSolutions Inc | Bought (not open market) | — |
| Feb 4, 2026 | SNDX Syndax Pharmaceuticals Inc | Bought (not open market) | — |
| Jan 10, 2026 | ELDN Eledon Pharmaceuticals, Inc | Bought (not open market) | — |
Companies traded
- EBS Emergent BioSolutions Inc: 2 sales, last Apr 30, 2026
- SNDX Syndax Pharmaceuticals Inc: 1 buy, 8 sales, last Feb 4, 2026
- ELDN Eledon Pharmaceuticals, Inc: other filings, last Jan 10, 2026
- RIGL Rigel Pharmaceuticals Inc: other filings, last May 19, 2021
- NVUS Novus Therapeutics, Inc: other filings, last Sep 11, 2020
- UROV Urovant Sciences Ltd: 1 sale, last Feb 19, 2020
- CBYL Carbylan Therapeutics, Inc: other filings, last Aug 3, 2015
- AVNR Avanir Pharmaceuticals, Inc: 1 buy, 44 sales, last Dec 17, 2014